Clinical remission remission induction. Medical search. Frequent questions

the median time from remission to relapse was 13 months and 15 months, respectively (P = 0.023, log rank test). (nih.gov)
We found that patients after induction chemotherapy plus G-CSF had similar overall survival (43% vs 40%, P = .88), event-free survival (37% vs 31%, P = .29), and relapse rates (34% vs 36%, P = .77) at 5 years as those not receiving G-CSF. (maastrichtuniversity.nl)
Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions. (medscape.com)
The maintenance phase evaluated the drug's ability to sustain remission and prevent relapse. (mountsinai.org)
Disease activity encompasses remission (complete absence of disease activity), response (quantifiable improvement in disease activity), and relapse (increase in disease activity from a previous low or absent state), which are used as outcomes in clinical trials 1 , 2 , 3 , 4 , 5 . (jrheum.org)
The 6-month remission rate (RR 1.09, 95% CI 0.86 to 1.38, p=0.48), the 6-month ANCA negativity (RR 1.31, 95% CI 0.91 to 1.90, p=0.15) and the long-term relapse rate (RR 1.36, 95% CI 0.80 to 2.31, p=0.26) were all similar between the two treatments. (bmj.com)
He recently initiated a clinical study to track large cohorts of AML patients by taking samples from diagnosis, after therapy induction, and every three months during remission until relapse. (weizmann.ac.il)
The purpose of this study is to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period. (mayo.edu)
Treatment of UC focuses on induction of remission (treatment of symptoms of active disease) and prevention of clinical relapse (resumption of symptoms of active disease) in patients in remission (known as maintenance therapy). (cochrane.org)
Therapeutic Candidate or Device TriLeukeVax, an autologous AML vaccine designed to stimulate induction of anti-leukemic cytolytic activity and improve relapse free survival (RFS). (ca.gov)
The primary outcomes were the clinical remission rate at week 16 and the cumulative relapse rate 48 weeks after receiving induction therapy. (biomedcentral.com)
Moreover, the cumulative rates of clinical relapse were not significantly different between the vedolizumab and tofacitinib groups in UC patients and between the vedolizumab and ustekinumab groups in CD patients ( p = 0.396 and p = 0.692, respectively). (biomedcentral.com)
Lower maternal educational level was associated with increased frequency of mucositis, as were induction chemotherapy and maintenance chemotherapy after relapse. (bvsalud.org)

We pooled data from several recent RA clinical trials and evaluated patients who had completed a 1-year treatment period (n = 629). (nih.gov)
The FDA approval was based on results from the phase 3 LUCENT-1 induction and LUCENT-2 maintenance trials, published last July in The New England Journal of Medicine . (medscape.com)
The trials showed that mirikizumab achieved primary and secondary endpoints, including sustained clinical remission and significantly improved bowel urgency. (medscape.com)
We conducted a pooled analysis of individual-level data from randomized clinical trials (RCTs) on induction therapy with infliximab and golimumab, accessed through the Yale University Open Data Access platform. (ecco-ibd.eu)
Participants were randomly assigned to receive 45 mg of upadacitinib or placebo (2:1) for induction therapy to assess its effectiveness in achieving remission in two double-blind phase 3 trials, U-EXCEL and U-EXCEED. (mountsinai.org)
Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. (emmes.com)
MMF pharmacokinetics were studied in a multicenter Blood and Marrow Transplant Clinical Trials Network randomized phase II trial evaluating the effectiveness of MMF as one of 4 agents added to corticosteroids as treatment of aGVHD. (emmes.com)
Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. (mcmaster.ca)
The approval is supported by data from PURSUIT clinical trials that evaluated patients with moderately to severely active UC who had previously failed or were intolerant to conventional treatments. (empr.com)
The international OMERACT Vasculitis Working Group has developed and implemented an iterative research agenda that has utilized accumulated experience and datasets from several multicenter clinical trials and large cohort studies. (jrheum.org)
This work has led to the development, evaluation, validation, and endorsement, through the OMERACT consensus and validation processes, of a "core set" of outcome measurements for use in clinical trials of AAV. (jrheum.org)
The research has utilized accumulated experience and datasets from several multicenter clinical trials and large cohort studies. (jrheum.org)
Core sets of outcome measures include the domains of the illness under study considered crucial to assess in clinical trials. (jrheum.org)
Data from three trials supported the FDA's regulatory greenlight: the induction studies U-EXCEED and U-EXCEL, and the maintenance study U-ENDURE. (biospace.com)
In this position paper we aimed to provide guidance from the global clinical research network (Pediatric Inflammatory Bowel Disease Network, PIBDnet) for designing clinical trials in PIBD in order to facilitate drug approval for children. (bmj.com)
Conclusion The viewpoints expressed in this paper could assist planning clinical trials in PIBD which are both of high quality and ethical, while remaining pragmatic. (bmj.com)
We've identified that our endpoints for clinical trials that use subjective criteria in both ulcerative colitis and Crohn's disease have not really represented a change in the management of patients. (crohnsforum.com)
When we did achieve clinical remission or mucosal healing in clinical trials, this translated into better long-term outcomes, with reductions in surgeries and hospitalizations. (crohnsforum.com)
It turns out that when we treat mucosal healing with any of the anti-TNF agents, and this is what's been looked at in clinical trials and reported this year, that we're actually finding better long-term outcomes and better sustained remissions in patients than when we use clinical outcomes alone. (crohnsforum.com)
Of course, it's not fair to compare agents across clinical trials, but I would say that the results with adalimumab are not quite what we expected and not quite as good as the results we've seen with infliximab in clinical trials in ulcerative colitis. (crohnsforum.com)
The aim of this review was followed through the recent literature survey on immunomodulatory effects and mechanisms of probiotics and FMT and also efficacy and safety of probiotics and FMT in clinical trials and applications. (hindawi.com)
This mutation's incidence is between 6% and 9% in AML, and clinical trials have provided conflicting prognostic information. (pharmacytimes.com)
In the ADVANCE and MOTIVATE induction trials, a significantly greater proportion of patients treated with SKYRIZI 600 mg IV achieved the co-primary endpoints of clinical remission (per SF/AP) and endoscopic response. (lifesciencesbc.ca)
In phase 3 clinical trials, we saw this therapy provide sustained improvement to patients with treatment-resistant depression. (ahdbonline.com)
Randomized controlled trials (RCTs) evaluating medical interventions for UC have traditionally used clinical disease activity indices which focus on subjective symptoms to define primary outcomes such as clinical remission or improvement. (cochrane.org)
The AbbVie press release describes how the approval of upadacitinib, was based on the results from three phase 3 clinical trials. (hospitalhealthcare.com)
The clinical efficacy comes from two induction trials, U-ACHIEVE induction and U-ACCOMPLISH and a single maintenance study U-ACHIEVE maintenance which are detailed in a single publication . (hospitalhealthcare.com)
in clinical trials, upadacitinib showed its ability to rapidly control symptoms in eight weeks for many participants and sustained responses at one year. (hospitalhealthcare.com)
The combination of infliximab with thiopurines has shown increased efficacy compared to infliximab alone in randomised placebo-controlled clinical trials and in real-life cohorts in both CD and UC. (medscape.com)

Using multivariable logistic regression modeling, we compared the primary outcome of clinical remission, and secondary outcomes of clinical response and mucosal healing, according to clinical trial definitions, between male and female patients with UC at week 6 (golimumab) or week 8 (infliximab) of induction therapy. (ecco-ibd.eu)
Compared to female patients, male patients were significantly less likely to achieve mucosal healing and clinical response in the treatment arm (aOR 0.47, 95% CI 0.27, 0.83 and 0.51, 95% CI 0.29, 0.90, respectively), but there was no significant difference in these secondary outcomes by sex in the placebo arm. (ecco-ibd.eu)
We are now learning that we can also use trough serum levels to help predict patterns of mucosal healing that are going to ultimately translate into longer-term remissions and hopefully aspects of disease modification such as improved outcomes, fewer hospitalizations, and certainly fewer surgeries. (crohnsforum.com)
5] While the investigators did identify meeting their primary endpoints, which were improved clinical remissions compared with patients treated with placebo, these outcomes did not seem as great as we've seen with the injectable anti-TNF agent infliximab. (crohnsforum.com)
Mutations in this particular gene are associated with a shorter duration of remission, decreased disease-free survival, and poor outcomes. (pharmacytimes.com)
An important and unanswered question concerns the impact of the number of conventional AML chemotherapy induction cycles to achieve first complete remission on transplant outcomes. (ascopost.com)
Similarly, the outcomes of myeloablative conditioning and reduced-intensity conditioning regimens for allo-HCT and their relationship with pretransplant consolidation cycles for patients in first complete remission are also unknown. (ascopost.com)
This large retrospective analysis on behalf of the CIBMTR shows again that among patients eligible for allo-HCT, only one induction cycle to achieve first complete remis sion, particularly when combined with one consolidation therapy, is associated with better outcomes after myeloablative conditioning and not reduced-intensity conditioning. (ascopost.com)
Compared with the poor outcomes of patients who received allo-HCT during refractory (active) disease, the outcomes of patients who received more than one induction cycle to achieve complete remission is somewhat better but remains unsatisfactory. (ascopost.com)
This personalized monitoring can be time-consuming and costly, and it is unclear whether it actually improves clinical outcomes. (eurekalert.org)
[ 13 ] Whether the combination of vedolizumab with anti-TNF can confer better clinical outcomes than each drug alone is yet unknown. (medscape.com)

The clinical value of chemotherapy sensitization of acute myeloid leukemia (AML) with G-CSF priming has remained controversial. (maastrichtuniversity.nl)
Cytarabine is a key constituent of remission induction chemotherapy. (maastrichtuniversity.nl)
A significant survival advantage of sensitizing AML for chemotherapy with G-CSF was not apparent in the entire study group, but it was seen in patients treated with escalated-dose cytarabine during remission induction. (maastrichtuniversity.nl)
EA9181, A Phase III Randomized Trial of Steroids+Tyrosine Kinase Inhibitor Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Rochester, Minn. This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. (mayo.edu)
PRIMARY OBJECTIVES: I. Determine maximum tolerated dose (MTD) of MEK162 (MEK inhibitor MEK162 ) in patients with RAS-mutated acute myeloid leukemia ( AML ) when combined with sequential induction chemotherapy (3 +4 ) as measured by development of grade 3-4 dose-limiting toxicities (DLT). (mycancergenome.org)
Perform preliminary efficacy analysis of combination of MEK162 and induction chemotherapy (3 +4 ) in patients with RAS-mutated AML by measuring complete remission rate, 2-year overall survival, and duration of response. (mycancergenome.org)
Oral lesions were associated with the induction phase of chemotherapy. (bvsalud.org)

Rinvoq met its primary and key secondary endpoints with its 45-mg dose in the two induction studies, and with its 15-mg and 30-mg doses in the maintenance study. (biospace.com)
In the FORTIFY maintenance trial, a significantly greater proportion of patients treated with SKYRIZI 360 mg SC achieved the co-primary endpoints of clinical remission (per SF/AP) and endoscopic response. (lifesciencesbc.ca)
Major secondary endpoints including the proportion of patients in clinical response, endoscopic healing, as well as improvement in health-related quality of life, were also significantly higher at week 8 among patients receiving STELARA compared with patients receiving placebo. (jnj.com)
The company achieved both co-primary endpoints of endoscopic response and clinical remission, as well as key secondary endpoints of rapid clinical response and corticosteroid-free clinical remission, with statistical significance. (yahoo.com)

Compared to female patients, male patients were significantly less likely to achieve clinical remission in both treatment and placebo arms (aOR 0.55, 95% CI 0.31, 0.97 and 0.34, 95% CI 0.15, 0.82, respectively, Figure). (ecco-ibd.eu)
Clinical remission is also less likely in male patients on placebo. (ecco-ibd.eu)
Patients who had a clinical response to upadacitinib induction therapy were then randomly assigned in the U-ENDURE maintenance trial to receive 15 mg or 30 mg of upadacitinib, or placebo (1:1:1) once daily for 52 weeks. (mountsinai.org)
Upadacitinib demonstrated superior efficacy over placebo, with a statistically significant proportion of patients achieving clinical remission after induction therapy. (mountsinai.org)
Similarly, greater proportions of patients in the Simponi group maintained clinical response compared with the placebo group through Week 54. (empr.com)
In ADVANCE and MOTIVATE, 43% and 35% of patients treated with SKYRIZI 600 mg IV achieved clinical remission at week 12, respectively, compared to 22% and 19% of patients receiving placebo. (lifesciencesbc.ca)
In FORTIFY, 52% of patients treated with SKYRIZI 360 mg SC achieved clinical remission at week 52 compared to 40% of patients receiving placebo. (lifesciencesbc.ca)
Additionally, during the induction studies, 24% and 19% of patients treated with SKYRIZI 600 mg IV achieved endoscopic remission at week 12, respectively, compared to 9% and 4% of patients receiving placebo. (lifesciencesbc.ca)
Esketamine was evaluated in the phase 3 TRANSFORM-2 study, a 4-week randomized, placebo-controlled, double-blind clinical trial. (ahdbonline.com)
Moderate quality evidence from the studies comparing adalimumab to placebo suggest that adalimumab may provide a benefit in terms of improved HRQL in people with UC receiving induction or maintenance therapy. (cochrane.org)
Results from the induction phase of the Phase 3 UNIFI study show that treatment with a single IV dose of STELARA induced clinical remission in a significantly greater proportion of UC patients at week 8, compared with placebo, at both doses studied. (jnj.com)
In a 2014 network meta-analysis, the authors concluded that compared to placebo, infliximab, adalimumab and golimumab are all effective for the induction and maintenance of remission in ulcerative colitis . (hospitalhealthcare.com)
In addition, data also supports the use of Janus kinase inhibitors in the management of UC, with a study of patients having moderately to severely active ulcerative colitis, finding that tofacitinib gave rise to a better clinical response and remission compared to those receiving placebo . (hospitalhealthcare.com)
In the induction studies, 45 mg dose of Rinvoq was used and dose strengths of 15 mg and 30 mg of Rinvoq were used in the maintenance study, compared with placebo. (yahoo.com)
The endoscopic response was observed in 34% and 46% of patients treated with a 45 mg dose of Rinvoq, in the two induction studies at week 12, respectively, compared with 3% and 13% of patients receiving placebo. (yahoo.com)
A clinical remission was achieved in 36% and 46% of patients treated with Rinvoq 45 mg, in the two induction studies at 12 weeks, respectively, compared with 18% and 23% of patients receiving placebo. (yahoo.com)
Moreover, 42% and 55% of patients treated with Rinvoq 15 mg and 30 mg achieved clinical remission at 52 weeks in the maintenance study, compared with 14% of patients receiving placebo. (yahoo.com)

Data from a phase 3 trial published today in The New England Journal of Medicine show that upadacitinib-a breakthrough, once-daily oral medication-helps patients achieve and maintain clinical and endoscopic remission. (mountsinai.org)
Corresponding author Jean-Frederic Colombel, MD , notes, "Upadacitinib addresses an unmet need in the treatment of Crohn's disease and allows patients access to an oral medication that could put them in clinical and endoscopic remission. (mountsinai.org)
During the ADVANCE and MOTIVATE induction studies, a significantly greater proportion of patients treated with SKYRIZI 600 mg IV achieved mucosal healing and endoscopic remission. (lifesciencesbc.ca)
Mucosal healing and endoscopic remission were observed during the FORTIFY maintenance trial in patients treated with SKYRIZI 360 mg SC. (lifesciencesbc.ca)

Corticosteroid-free remission and corticosteroid-free response were experienced by 30% and 54%, respectively, of the entire cohort, and were similar between the two groups. (medscape.com)

Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis - a clinical randomized controlled trial. (smw.ch)
To learn more, researchers in Norway launched the first open-label, multi-center, randomized, controlled trial to assess its effectiveness in achieving remission in patients with several inflammatory diseases. (eurekalert.org)

To determine the tolerability of combination therapy with ruxolitinib and Early Intensification therapy in patients with activation of JAK-STAT signaling that can be inhibited by ruxolitinib and Day 15 or Day 22 MRD ≥5%, Day 42 MRD ≥1%, or LLy patients without complete response at the End of Induction and all patients with early T cell precursor leukemia. (centerwatch.com)
To use data from clinical genomic sequencing of diagnosis, germline/remission and MRD samples to guide therapy, including incorporation of targeted agents and institution of genetic counseling and cancer surveillance. (centerwatch.com)
Genomic analyses have revolutionized our understanding of the molecular taxonomy of ALL, and these advances have led the push to implement genome and transcriptome characterization in the clinical management of ALL to facilitate more accurate risk-stratification and, in some cases, targeted therapy. (haematologica.org)
This review describes key advances in our understanding of the biology of ALL and optimal approaches to risk-stratification and therapy, and it suggests key areas for basic and clinical research. (haematologica.org)
We conducted a systematic review and meta-analysis to assess the efficacy of MMF as a remission induction therapy in patients with AAV comparing it with the efficacy of CYC. (bmj.com)
MMF may be an alternative remission induction therapy in patients with non-life-threatening AAV. (bmj.com)
The efficacy of intensive immunosuppressive therapy with agents such as cyclophosphamide (CYC) or rituximab (RTX) has been established as a remission-inducing therapy in patients with organ/life-threatening AAV 1-5 and is recommended as a conventional therapy. (bmj.com)
Recently, the monoclonal antibody rituximab was approved for the treatment of GPA and MPA, providing the first major alternative to cyclophosphamide for induction therapy of AAV. (smw.ch)
If the patient responds completely and goes into remission, he or she progresses to consolidation with postremission therapy or transplant. (pharmacytimes.com)
In both cases-incomplete response or complete remission—if the disease eventually relapses, clinicians will move to salvage therapy. (pharmacytimes.com)
The goals of therapy for AML include complete remission, restoration of normal hematopoietic functions, and no evidence of measurable residual disease. (pharmacytimes.com)
Retrospective analysis by the Center for International Blood and Marrow Transplant Research (CIBMTR): Prompt complete remission plus consolidation therapy yields improved survival after allogeneic hematopoietic cell transplantation (allo-HCT) for patients with acute myeloid leukemia (AML) receiving a myeloablative conditioning regimen and not a reduced-intensity conditioning regimen. (ascopost.com)
NORTH CHICAGO, IL - AbbVie (NYSE: ABBV) announced the European Commission (EC) approved SKYRIZI ® (risankizumab, 600 mg intravenous [IV] induction and 360 mg subcutaneous [SC] maintenance therapy) as the first specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy. (lifesciencesbc.ca)
High quality evidence suggests that infliximab provides a clinically meaningful improvement in HRQL in UC patients receiving induction therapy. (cochrane.org)
High quality evidence shows that TNF-α antagonists (as a class of biologics) provide a clinically meaningful improvement in HRQL in UC patients receiving induction therapy. (cochrane.org)
After prior anti-TNF therapy failure, vedolizumab and tofacitinib in UC patients and vedolizumab and ustekinumab in CD patients were not significantly different in terms of the efficacy in inducing and maintaining a clinical response. (biomedcentral.com)
However, recently, "treat-to-target therapy" has been used to reduce complications and improve patients' quality of life based not only on clinical symptoms but also on the normalisation of bowel structure and function through mucosal healing [ 2 ]. (biomedcentral.com)
In addition, a secondary loss of response, defined as worsening of symptoms, can occur as a result of active IBD during maintenance therapy in patients with prior disease control after induction therapy. (biomedcentral.com)
Induction immunochemotherapy was followed by obinutuzumab maintenance therapy. (cdc.gov)

FMT has also been clinically applied to inflammatory bowel disease (IBD), irritable bowel syndrome, chronic functional constipation, intestinal cancer, foodborne allergic gastroenteropathy, and so on [ 8 ], and researchers have achieved a certain clinical efficacy. (hindawi.com)
Our aim was to evaluate the clinical efficacy, drug sustainability, frequency of dose intensification, and results from therapeutic drug monitoring in UST treated Crohn's disease (CD) patients using a prospective, nationwide, multicenter cohort from Hungary. (ecco-ibd.eu)
Ustekinumab showed good drug sustainability and clinical efficacy in a population with severe disease phenotype and high rates of previous anti-TNF failure, however frequent and early dose intensification was required. (ecco-ibd.eu)
Despite the high efficacy of anti-TNF agents, approximately 10-40% of patients do not experience an improvement in clinical signs or symptoms after the induction phase, defined as a primary non-response [ 5 ]. (biomedcentral.com)
Conclusions Vedolizumab/anti-TNF co-exposure did not generate new safety signals during 14-weeks induction, nor did it reduce efficacy or alter vedolizumab pharmacokinetics. (medscape.com)

Data from patient demographics, disease phenotype, treatment history (surgical history, prior and present medical therapies), clinical disease activity (using the Crohn's Disease Activity Index (CDAI), Harvey Bradshaw Index (HBI)), biomarkers (C-reactive protein - CRP), and therapeutic drug monitoring were captured. (ecco-ibd.eu)

Janssen Biotech) to induce and maintain clinical response in adults with ulcerative colitis. (empr.com)
For instance, at this year's meeting, the results of a clinical trial with adalimumab in ulcerative colitis were presented. (crohnsforum.com)
PHILADELPHIA, PENNSYLVANIA, October 9, 2018 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data showing treatment with a single intravenous (IV) dose of STELARA ® (ustekinumab) induces clinical remission and response in adults with moderate to severe ulcerative colitis (UC) who previously experienced an inadequate response or were intolerant to conventional or biologic therapies. (jnj.com)
Ulcerative colitis is a complex immune disease, and more than half of UC patients have not experienced remission with currently available conventional or biologic treatment options," said lead investigator Bruce E. Sands, MD, Dr. Burrill B. Crohn Professor of Medicine and Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai. (jnj.com)

ATLANTA -- New research presented at ACR Convergence, the American College Rheumatology's annual meeting, showed that patients with rheumatic diseases whose infliximab treatment was individually assessed and adjusted with a new strategy called therapeutic drug monitoring did not achieve remission at higher rates compared to those who received standard care. (eurekalert.org)
Our study does not support therapeutic drug monitoring be applied as a general treatment strategy during induction of infliximab. (eurekalert.org)

Clinical features and outcome of pediatric Wegener's granulomatosis. (medscape.com)
This increased clinical trial activity in vasculitis has been accompanied by the development and validation of new outcome measures - a challenging process for these complex, multiorgan system diseases. (jrheum.org)

According to their results, therapeutic drug monitoring was not superior to standard treatment for achieving disease remission at 30 weeks in people with a range of rheumatic diseases. (eurekalert.org)
In the study's therapeutic drug monitoring arm, 100 or 53% of patients achieved remission, while 106 or 54% of the patients in the standard treatment group also achieved remission. (eurekalert.org)
Despite a lack of clinical trial data and diverging guidelines, proactive therapeutic drug monitoring has already been adopted in clinical practice across different specialities. (eurekalert.org)
Future research should explore if more targeted applications of therapeutic drug monitoring, such as assessment of serum drug levels in treatment failures, could be a useful clinical tool, she adds. (eurekalert.org)
At the end of the induction phase (weeks 1-4), the evidence of therapeutic benefit should be assessed to establish whether continued esketamine treatment is needed. (ahdbonline.com)

Based on this analysis of pooled data from RCTs, we demonstrate that clinical remission, response and mucosal healing with TNFi induction therapies are less likely in male patients compared to female patients with UC. (ecco-ibd.eu)
At week 8, patients (n=961) were evaluated for clinical remission, endoscopic healing, clinical response, change from baseline in the IBDQ score, and mucosal healing (an endpoint that includes both endoscopic healing and histologic healing). (jnj.com)

Data showed significantly greater proportions of patients in the Simponi group achieved clinical response, remission, and improvement at Week 6. (empr.com)
The purpose of this study is to evaluate the rate of complete MRD response by flow cytometry after 4 weekly doses of daratumumab-hyaluronidase (Day 29) among patients with MRD positive T-ALL in hematologic morphologic complete remission or complete remission with incomplete hematologic recovery. (mayo.edu)
A typical course of treatment for a patient with AML includes induction, followed by re-induction if the patient has an incomplete response. (pharmacytimes.com)
He also indicated that induction failure is failure to attain a complete response following at least 2 courses of induction. (pharmacytimes.com)
The dosing frequency should be tailored to the least frequent dose necessary to maintain remission or clinical response. (ahdbonline.com)
Clinical response and remission rates were 78.1% and 57.7% using CDAI, and 82.5% and 51.8% based on HBI scores after induction treatment (w8). (ecco-ibd.eu)
In the past, the only aim of IBD treatment was to achieve and maintain clinical remission and a clinical response. (biomedcentral.com)
Week 14 clinical remission was attained in 10/25 (40%) of VDZ-aTNF patients versus 23/50 (46%) of VDZ patients (OR = 0.8, 95% CI 0.3-2.1, P = 0.6) and clinical response in 19/25 (76%) versus 39/50 (78%) respectively (OR = 0.9, 95% CI 0.3-2.7, P = 0.8). (medscape.com)
The initial dose should be maintained or adjusted until the clinical response is satisfactory and, if no suitable clinical response is obtained after a reasonable period of time, [CV004 trade name] should be stopped and the patient's treatment changed. (who.int)
Once an initial favourable response has been obtained, the initial dose should be reduced in small amounts until the lowest dose that maintains a suitable clinical response is obtained. (who.int)

The significant rates of remission observed through the 8-week induction, coupled with a safety profile that is well-documented through years of research and use in other immune diseases, demonstrate the potential for ustekinumab as an effective treatment for UC. (jnj.com)
In CD patients, the clinical remission rates were not significantly different between the vedolizumab and ustekinumab groups (53.6% vs. 50.0%, p = 0.820). (biomedcentral.com)

Future prospective studies are required to test different strategies that can improve the rates and quality (based on measurable residual disease [MRD] assessment) of remissions prior to and after allo-HCT using less toxic and more effective induction, conditioning, and maintenance therapies. (ascopost.com)

Rinvoq likewise led to significantly better clinical remission rates, which ranged from 36% to 46% in the two induction studies and 18% to 23% in the maintenance study. (biospace.com)

The Journal of Allergy and Clinical Immunology, 151 (2), 416-419. (immunetolerance.org)
Clinical Immunology, Epub ahead of print. (immunetolerance.org)

We compared levels of functional impairment and radiographic progression among patients meeting the ACR 50% or 70% improvement criteria (ACR50 and ACR70 responders, respectively) who attained remission of disease, low disease activity, or moderate disease activity after 1 year, as assessed by the Simplified Disease Activity Index and the Disease Activity Score in 28 joints. (nih.gov)
Also, Simponi has been approved to induce clinical remission and achieve and sustain clinical remission in induction responders. (empr.com)

Existing treatment options often fall short in achieving sustained remission and controlling symptoms. (mountsinai.org)

The presence of such secondary aberrations did not correlate with any morphological or clinical characteristics, including survival. (lu.se)

However, the clinical manifestations of splenic mucormycosis are non-specific, leading to frequent delays in diagnosis. (frontiersin.org)
In a multicenter trial, patients with symptomatic clinical stage I and stage II and III multiple myeloma were registered at diagnosis and those who responded to melphalan-prednisone (MP) were randomized either to receive interferon (2 mU/m2) subcutaneously three times per week or no maintenance. (mcmaster.ca)
Critically ill infants and children with rare diseases need equitable access to rapid and accurate diagnosis to direct clinical management. (cdc.gov)

22 of these (91%) entered a complete remission (CR). (lu.se)
01). Treatment-related mortality was similar for patients with primary induction failure vs those in first complete remission after myeloablative or reduced-intensity conditioning allo-HCT (Table 1). (ascopost.com)
5,6 Achieving and sustaining complete remission early in the treatment sequence is a crucial goal for patients with MDD. (ahdbonline.com)
A 67-year-old woman with non-Hodgkin lymphoma showed complete remission after 6 cycles of treatment with bendamustine and obinutuzumab. (cdc.gov)

In the MTX group, remission was delayed among patients with more extensive disease (P = 0.04) or pulmonary involvement (P = 0.03). (nih.gov)
The MTX regimen used in the present study was less effective for induction of remission in patients with extensive disease and pulmonary involvement and was associated with more relapses than the CYC regimen after termination of treatment. (nih.gov)
American College of Rheumatology [ACR] responder status) with the value of evaluating absolute disease activity states (e.g., remission). (nih.gov)
Within the ACR50 and ACR70 responder groups, functional disability and radiographic progression were lowest in patients who had attained disease remission at 1 year, compared with those who had attained low or moderate disease activity. (nih.gov)
Assessing actual disease activity as well as disease activity states should constitute an integral part of clinical trial data reporting. (nih.gov)
The patient's clinical presentation is primarily determined by the location and extent of the disease. (medscape.com)
State-of-the-art basic and clinical science of Kawasaki disease. (medscape.com)
Dr. Colombel is the co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at The Mount Sinai Hospital in New York City and Professor of Medicine (Gastroenterology) at the Icahn School of Medicine at Mount Sinai. (mountsinai.org)
I'd like to give you some updates regarding the clinical field of inflammatory bowel disease [IBD] from this year's meeting. (crohnsforum.com)
In sera derived from patients with chronic inflammatory demyelinating polyneuropathy, an autoimmune disease of the peripheral nervous system in which humoral immune responses mediate tissue damage, induction of IgG Fc sialylation was associated with clinical disease remission. (jci.org)
The follow up dose for adult patients with GPA and MPA who have achieved disease control with induction treatment, in combination with glucocorticoids is two 500 mg intravenous infusions separated by two weeks, followed by a 500 mg intravenous infusion every 6 months thereafter based on clinical evaluation ( 2.6 ). (drugs.com)
In this retrospective analysis, the investigators assessed the impact of the number of induction and consolidation cycles and disease status on the success of allo-HCT in 3,113 patients with AML from 2008 to 2019. (ascopost.com)
The EC approval for SKYRIZI in Crohn's disease is supported by results from the global Phase 3 program, which included three studies: ADVANCE induction, MOTIVATE induction and FORTIFY maintenance. (lifesciencesbc.ca)
whilst both may present with similar clinical features, they are best considered as distinct disease entities since the underlying pathophysiology and treatment strategies are very different. (dovepress.com)
The patient should be observed closely for signs that the dose may need to be altered, such as changes in clinical status resulting from disease remissions or exacerbations. (who.int)
DESCRIPTION: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the treatment of anemia and iron deficiency in adult patients with heart disease. (bvsalud.org)
DESCRIPTION: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the screening, monitoring, and treatment of adults with stage 1 to 3 chronic kidney disease. (bvsalud.org)

Patients may receive a second course of induction at the discretion of the principal investigator. (mycancergenome.org)

The clinical remission rates were not significantly different between the vedolizumab and tofacitinib groups in UC patients (56.8% vs. 46.2%, p = 0.509). (biomedcentral.com)

My clinical work focuses on the treatment of individuals with a pre-leukemic condition called myelodysplastic syndrome," he says. (weizmann.ac.il)
In 2010, the United States recommended FMT as a treatment plan for CDI in their clinical guidelines [ 7 ]. (hindawi.com)
This study highlights the need for thorough evaluation of monitoring tools and treatment strategies before their implementation in clinical care," says Dr. Syversen. (eurekalert.org)
In a follow-up as IBS is often a source of great distress and article [9], the investigators reported that the point at which a patient seeks profes- clinical improvement was maintained in all sional help is of major significance and the hypnotherapy patients during a 2-year often decisive for the results of treatment. (who.int)
Vaccine recommendations are based on characteristics of the immunobiologic product, scientific knowledge regarding the principles of active and passive immunization, the epidemiology and burden of diseases (i.e., morbidity, mortality, costs of treatment, and loss of productivity), the safety of vaccines, and the cost analysis of preventive measures as judged by public health officials and specialists in clinical and preventive medicine. (cdc.gov)

Dr. Gubatan's work has been featured in Gastroenterology, Gut, American Journal of Gastroenterology, Clinical Gastroenterology and Hepatology, Alimentary Pharmacology and Therapeutics, Journal of Crohns & Colitis, and Inflammatory Bowel Diseases. (stanford.edu)

U-EXCEED had an additional 12-week open-label, active single-group induction period to allow for the accrual of enough patients for entry into U-ENDURE. (mountsinai.org)
The study's primary endpoint was remission at week 30. (eurekalert.org)

The dose for RA in combination with methotrexate is two-1,000 mg intravenous infusions separated by 2 weeks (one course) every 24 weeks or based on clinical evaluation, but not sooner than every 16 weeks. (drugs.com)
The induction dose for adult patients with active GPA and MPA in combination with glucocorticoids is 375 mg/m 2 once weekly for 4 weeks. (drugs.com)

Dr. Shlush continues to collaborate with his postdoctoral mentor, Dr. John E. Dick, and clinical mentor, Dr. Mark Minden, at Princess Margaret to study AML and other blood malignancies. (weizmann.ac.il)
The FDA approval was based on positive data from two induction studies, U-EXCEED and U-EXCEL and one maintenance study, U-ENDURE. (yahoo.com)
Only one new report from an original epidemiology study in relation to leukemia induction by formaldehyde has been published since the last review. (who.int)

In 2012, he packed his bags for the University of Toronto, where he spent the next few years as both a postdoctoral research fellow and a clinical fellow with a focus on leukemia at Princess Margaret Cancer Centre. (weizmann.ac.il)
Several possible mechanisms were considered for the induction of human leukemia, such as clastogenic damage to circulatory stem cells. (who.int)
Therefore, on the basis of the data available at this time, it was not possible to identify a mechanism for the induction of myeloid leukemia in humans. (who.int)

Twenty-nine consecutive cases with a t(8;21)(q22;q22) in the bone marrow (BM) karyotype were retrospectively studied concerning clinical, morphological and cytogenetic data. (lu.se)

To assess clonal diversity and evolution of pre-leukemic and leukemic populations using DNA variant detection and single-cell genomic analyses in a non-clinical, research setting. (centerwatch.com)

[ 6-8 ] Results were more mixed for combination adalimumab-thiopurines in a controlled trial and in observational studies, [ 9-11 ] possibly indicating that for both agents the benefit of concomitant thiopurines may be dependent on the clinical context in which they are given. (medscape.com)

Anatomy10

Organisms1

Diseases44

Chemicals and Drugs69

Analytical, Diagnostic and Therapeutic Techniques and Equipment55

Psychiatry and Psychology2

Phenomena and Processes20

Anthropology, Education, Sociology and Social Phenomena1

Information Science4

Health Care20

Relapse13

Trials29

Outcomes11

Chemotherapy7

Endpoints4

Placebo17

Endoscopic remission4

Corticosteroid-free1

Randomized Contr2

Therapy19

Efficacy5

Crohn's Disea1

Ulcerative4

Infliximab2

Outcome2

Therapeutic5

Mucosal Healing2

Response10

USTEKINUMAB2

Therapies1

Better clinical1

Immunology2

Responders2

Symptoms1

Secondary1

Diagnosis3

Complete4

Disease17

Principal investigator1

Tofacitinib1

Treatment5

Inflammatory1

Week2

Weeks2

Study3

Leukemia3

Retrospectively1

Assess1

Adalimumab1